Ken Fisher Prothena Corp Public LTD CO Transaction History

Fisher Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Jul 09, 2018	SELL	$10.99 - $44.21 $302,060 - $1.22 Million	-27,485 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$27.95 - $45.04 $327,434 - $527,643	-11,715 Reduced 29.89%	27,485 $1.01 Million
Q1 2018 Apr 19, 2018	BUY	$27.95 - $45.04 $327,434 - $527,643	11,715 Added 42.62%	39,200 $1.44 Million
Q4 2017 Jan 24, 2018	BUY	$35.44 - $63.76 $201,015 - $361,646	5,672 Added 26.0%	27,485 $1.03 Million
Q3 2017 Oct 17, 2017	BUY	$53.83 - $67.75 $1.17 Million - $1.48 Million	21,813	21,813 $1.41 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.